Diagnostic and prognostic value of the new tumour marker CYFRA 21-1 in patients with squamous cell lung cancer.

Abstract

We wanted to investigate the diagnostic and prognostic significance of serum CYFRA 21-1, especially in predicting the risk of recurrence in patients with operable squamous cell lung cancer. Serum levels of CYFRA 21-1 were measured using an immunoradiometric assay (CIS bio) in 76 patients with squamous cell lung cancer (64 operable and 12 with unresectable tumours), 22 with other non-small-cell type (12 with adenocarcinoma and 10 with large-cell type) and 45 with nonmalignant lung diseases. Elevated preoperative CYFRA 21-1 levels were identified in 63% of patients with squamous cell type (SqCC), 33% with adenocarcinoma, and 30% with large-cell carcinoma type. The diagnostic specificity of the assay was 96%. Positive CYFRA 21-1 levels were observed in 33% of stage I, 52% of stage II, 76% of stage IIIa and 83% of stage IIIb patients with SqCC type. Statistically significant differences were obtained between stages I and II and between II and IIIa, but not between stages IIIa and IIIb. Recurrence-free survival probability for patients with elevated serum CYFRA 21-1 levels before surgery was 63% (24/38) versus 92% (24/26) for patients with normal serum CYFRA 21-1 levels. However, the difference was not statistically significant when adjusted for the TNM stage (primary tumour, regional lymph node involvement, occurrence of distant metastasis). In 9 of the 10 patients with increased trend for CYFRA 21-1 during follow-up, elevated serum CYFRA 21-1 levels preceded (7) or coincided (2) with the clinical detection of tumour recurrence, providing a predictive value of an increased trend of 90%.(ABSTRACT TRUNCATED AT 250 WORDS)

• Authors: J Niklinski, M Furman, E Chyczewska, L Chyczewski, F Rogowski, J Laudanski
• Journal: The European respiratory journal (Eur Respir J) Vol. 8 Issue 2 Pg. 291-4 (Feb 1995) ISSN: 0903-1936 [Print] England
• PMID: 7538933 (Publication Type: Journal Article)

Chemical References

• Biomarkers, Tumor
• Keratins

Topics

• Adenocarcinoma (blood, diagnosis, mortality)
• Biomarkers, Tumor (blood)
• Carcinoma, Non-Small-Cell Lung (blood, diagnosis, mortality)
• Carcinoma, Squamous Cell (blood, diagnosis, mortality)
• Humans
• Immunoradiometric Assay
• Keratins (blood)
• Lung Neoplasms (blood, diagnosis, mortality)
• Multivariate Analysis
• Neoplasm Recurrence, Local (epidemiology)
• Prognosis
• Proportional Hazards Models
• Risk Factors
• Sensitivity and Specificity
• Survival Analysis